Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01469247 · ClinicalTrials.gov registry record · Phase 1
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01469247: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01469247 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01469247, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy. You will receive photon radiation therapy. This type of radiation is similar to the radiation you have already had. Conformal radiotherapy or intensity modulated radiotherapy (IMRT) will be used to try to treat the tumor while affecting as little of the surrounding normal tissue as possible.
Interventions
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-12-07 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01469247
The ClinicalTrials.gov registry entry for NCT01469247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT01469247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01469247 about?
NCT01469247 is a clinical study titled "Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)". The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy. You will receive photon radiation therapy. This type of radiation is similar to the radiation you have already had. Conformal...
What is the current status of trial NCT01469247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-12-07. Estimated completion is 2022-09-20.
What interventions are being tested in trial NCT01469247?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01469247?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.